ReviewThe Psychiatric clinics of North America2010
The promise and reality of pharmacogenetics in psychiatry.
Review in The Psychiatric clinics of North America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 51 citations in OpenAlex.
- Shared and distinct alterations of white matter tracts in remitted and nonremitted patients with schizophrenia.Human brain mapping · 2018Article
- Anticipating the Ethical Challenges of Psychiatric Genetic Testing.Current psychiatry reports · 2017Review
- Medication-free Alternatives for Long-term Maintenance of Bipolar Disorder: A Case Series.Global advances in health and medicine · 2015Article
- Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report.International journal of molecular sciences · 2015Article
- Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response.Patient education and counseling · 2014Review
- Neurotrophic tyrosine kinase receptor type 2 (NTRK2) gene associated with treatment response to mood stabilizers in patients with bipolar I disorder.Journal of molecular neuroscience : MN · 2013Article
- Using a pharmacogenomic algorithm to guide the treatment of depression.Translational psychiatry · 2012Article
- Cardiometabolic Health in Bipolar Disorder.Psychiatric annals · 2012Article
- Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes.Biomarkers in medicine · 2011Article
- Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Existing psychotropic medications for the treatment of mental illnesses, including antidepressants, mood stabilizers, and antipsychotics, are clinically suboptimal. They are effective in only a subset of patients or produce partial responses, and they are often associated with debilitating side effects that discourage adherence. There is growing enthusiasm in the promise of pharmacogenetics to personalize the use of these treatments to maximize their efficacy and tolerability; however, there is still a long way to go before this promise becomes a reality. This article reviews the progress that has been made in research toward understanding how genetic factors influence psychotropic drug responses and the challenges that lie ahead in translating the research findings into clinical practices that yield tangible benefits for patients with mental illnesses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.